Atea Pharmaceuticals Inc
AVIR
Market Cap$254.87M
Close$
$0.75
72.9% downside
Current Fair Value
72.9% downsideOvervalued by 72.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $254.87 Million |
|---|---|
| Enterprise Value | $191.81 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2 |
| Beta | 0.17 |
| Outstanding Shares | 84,463,059 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.49 |
|---|---|
| PEG | 24.88 |
| Price to Sales | - |
| Price to Book Ratio | 0.55 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.96 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Atea Pharmaceuticals Inc
39 employeesAtea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding of...